Nutrition, Gut Microbiota and Immunity: Therapeutic Targets for IBD

Editors

James D. Lewis  Philadelphia, PA, USA
Frank M. Ruemmele  Paris, France
Gary D. Wu  Philadelphia, PA, USA
The material contained in this volume was submitted as previously unpublished material, except in the instances in which credit has been given to the source from which some of the illustrative material was derived.

Great care has been taken to maintain the accuracy of the information contained in the volume. However, neither Nestec Ltd. nor S. Karger AG can be held responsible for errors or for any consequences arising from the use of the information contained herein.

© 2014 Nestec Ltd., Vevey (Switzerland) and S. Karger AG, Basel (Switzerland). All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or recording, or otherwise, without the written permission of the publisher.

Printed on acid-free and non-aging paper
ISBN 978-3-318-02669-6
ISSN 1664–2147
e-ISSN 1664–2155
Contents

VII Preface
IX Foreword
XIII Contributors

Pathogenesis of IBD

1 A Review of the Epidemiology of Inflammatory Bowel Disease with a Focus on Diet, Infections and Antibiotic Exposure
   Lewis, J.D. (USA)

19 Current Issues in the Design of Clinical Trials in IBD
   Feagan, B.G. (Canada)

29 The Intestinal Microbiota in Inflammatory Bowel Diseases
   Sartor, R.B. (USA)

41 Genetics and Innate and Adaptive Immunity in IBD
   Zanello, G.; Kevans, D.; Goethel, A.; Silverberg, M.; Tyler, A.; Croitoru, K. (Canada)

57 Interplay of Nutrients and Microbial Metabolites in Intestinal Immune Homeostasis: Distinct and Common Mechanisms of Immune Regulation in the Small Bowel and Colon
   Perrigoue, J.; Das, A.; Mora, J.R. (USA)

Manipulating the Gut Microbiome as a Therapy for IBD

73 Diet, the Gut Microbiome and the Metabolome in IBD
   Wu, G.D. (USA)

83 Antibiotics, Probiotics and Prebiotics in IBD
   Bernstein, C.N. (Canada)

101 Fecal Microbiota Transplantation: An Interest in IBD?
   Kahn, S.A.; Goeppinger, S.R.; Rubin, D.T. (USA)
The Future of Nutrition in IBD

115  Enteral Nutrition as Treatment Option for Crohn’s Disease: In Kids Only?  
Ruemmele, F.M.; Pigneur, B.; Garnier-Lengliné, H. (France)

125  Effects of Exclusive Enteral Nutrition on Bone Mass, Linear Growth and Body Composition in Children with Crohn’s Disease  
Sylvester, F.A. (USA)

131  Exclusive Enteral Nutrition: Clues to the Pathogenesis of Crohn's Disease  
Levine, A. (Israel)

141  Current State of the Art of Medical Foods  
Blum, S. (Switzerland); Brito, F. (USA)

153  IBD Therapy: New Targets and Unmet Needs  
Colombel, J.-F. (USA)

161  Concluding Remarks

163  Subject Index
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic debilitating diseases that occur in populations around the world. The diseases can manifest at any age, and therefore represent a clinical challenge for pediatricians, internists, family practitioners, and surgeons. The underlying etiology is multifactorial, where host genetic polymorphisms account for a minority of the risk for disease development, emphasizing the importance of environmental factors such as the gut microbiota. Supportive of this notion, epidemiologic associations show a significant increase in IBD incidence over the past few decades associated primarily with residence in industrialized nations.

Current therapeutic modalities for IBD are largely targeted at suppression of the innate and adaptive immune response. Commonly used therapies include mesalamine, corticosteroids, thiopurine analogues (azathioprine or 6-mercaptopurine), methotrexate, and anti-tumor necrosis factor-α agents. There is also limited use of natalizumab, a biologic targeting the α4-integrin adhesion molecules. While effective for many patients, these therapeutic strategies are not universally effective. Furthermore, they are each associated with the risk of serious and sometimes fatal adverse events.

An alternative approach to the treatment of IBD is to change the environmental factors that contribute to the etiology or perpetuation of inflammation. Leading targets for this alternative approach to therapy are the principal contents of the gastrointestinal tract – our diet and the human gut microbiota. Indeed, there is reason to believe that the composition of our diet and the gut microbiota might have a synergistic effect on inflammation related to IBD.

This monograph includes summaries of talks presented at the 79th Nestlé Nutrition Institute Workshop held in New York on the 28th and 29th of September 2013. The speakers in the symposium addressed our current understanding of the epidemiology and biologic underpinnings that manifest as CD and UC; the gut microbiota, its function, and how it may interact with
nutritional status in perpetuating IBD; the potential for manipulation of the gut microbiota through the use of prebiotics, probiotics, antibiotics, and fecal transplantation, and the current role of and future prospects for nutritional interventions in the management of these diseases.

Despite advances in the treatment of IBD, a substantial proportion of patients experience relapse of the disease every year. Many of these patients still require surgery. Although surgery represents a cure for UC, it is associated with lifelong alteration in bowel function and risks of other complications. For CD, surgery is generally only a temporizing measure as disease recurrence is common. Given the incomplete effectiveness of our current immunosuppressive therapies and their associated toxicities, there is a real need for alternative treatment strategies. Altering key environmental exposures that drive the inflammatory response could open new avenues to treat these debilitating lifelong diseases.

James D. Lewis
Frank M. Ruemmele
Gary D. Wu
Foreword

Inflammatory bowel disease (IBD) currently affects 1 in 200 people in the United States. The incidence of IBD has been gradually increasing globally in the past several decades. While the explanation for this increase is not totally clear, environmental factors, including changes in the diet, may be a key factor.

The 79th Nestlé Nutrition Institute Workshop held in New York City in September 2013 carries on the theme from the 77th Nestlé Nutrition Institute Workshop, where world experts gathered in Panama City to present their latest findings on how nutrient status can modulate immunity and improve health conditions in pediatric patients. This workshop chaired by Prof. Lewis, Prof. Ruemmele and Prof. Wu focused on the complex relationship between nutrition, inflammation and the microbiome as it relates to IBD; this is arguably the hottest area of IBD research currently.

Previously, the theories on pathogenesis of IBD suggested a combination of genetic susceptibility and immune and external environmental factors. In recent years, the gut microbiota has greatly gained in importance and has been accepted as the 4th element in the pathogenesis of IBD. These relationships are complex and not independent since IBD patients may have a genetic susceptibility that leads to abnormal immune responses directed against the intestinal microbiota.

Currently, over 160 genetic susceptibility genes have been identified for IBD, the most prevalent of these are Nod2, an important intracellular pathogen recognition sensor, and ATG 16L1, important in autophagy, killing and processing of phagocytized bacteria. However, the function of many of the other genes identified has not been fully characterized.

The gut microbiota consists of both protective and aggressive microbes, and the balance between these populations is important, not only in the pathogenesis of IBD, but also in the ongoing inflammatory response. A better understanding of the complex interactions, particularly the role of the gut microbiota in the inflammatory process, holds the key for potential for targeted therapy in
the future. The ability to selectively alter the composition and thus the function of the gut microbiome through diet, prebiotic and probiotic therapy may be a very attractive treatment alternative for patients with IBD. There is already good evidence in the medical literature that total enteral nutrition is highly efficacious in inducing remission in pediatric Crohn’s disease. In these patients, there is a significant shift in the gut microbiota following the successful enteral therapy; however, the causal relationship has not been established to date.

On behalf of Nestlé Nutrition Institute and Nestlé Health Science, we would like to thank the Chairmen, Prof. James Lewis, Prof. Frank M. Ruemmele and Prof. Gary Wu for their diligent work in assembling such a distinguished group of researchers, clinicians and speakers. We would also like to thank all the speakers for their hard work in putting together such outstanding presentations. The energy throughout the meeting, the interest among the participants and the quality of the questions posed to the speakers were all testaments to the quality of the meeting and the importance of this topic. We hope that important collaborations will result from the many positive interactions during this workshop.

Finally, we would like to thank Natalia Wagemans, Mélanie Costinas, Bernice Hammer and Mélanie Pittier who worked tirelessly in the background to ensure the meeting ran smoothly and made it the resounding success that it was.

We look forward to a follow-up NNI Workshop in the near future to review the advances in this exciting field of research.

Emil Chuang, MD
Global Medical Affairs Manager
Nestlé Health Science
Vevey, Switzerland

Ferdinand Haschke, MD, PhD
Chairman
Nestlé Nutrition Institute
Vevey, Switzerland
79th Nestlé Nutrition Institute Workshop
New York, NY, September 27–29, 2013
Contributors

Chairpersons & Speakers

Dr. Charles Bernstein
University of Manitoba
804F-715 McDermot Ave
Winnipeg, MB R3E03P
Canada
E-Mail Charles.bernstein@med.umanitoba.ca

Dr. Stephanie Blum Sperisen
Nestlé Health Science
Rue des Ramparts 2
CH–1095 Lutry
Switzerland
E-Mail stephanie.blumsperisen@nestle.com

Prof. Jean-Frederic Colombel
Mount Sinai School of Medicine
Henry D. Janowitz Division of Gastroenterology
1 Gustave L. Levy Place, Box 1069
New York, NY 10029
USA
E-Mail jean-frederic.colombel@mssm.edu

Dr. Kenneth Croitoru
University of Toronto
Division of Gastroenterology
Mount Sinai Hospital, Room 437
600 University Avenue
Toronto, ON M5G 1X5
Canada
E-Mail Kcroitoru@mtsniain.on.ca

Prof. Brian G. Feagan
Robarts Clinical Trials Inc.
100 Perth Drive
London, ON N6A 5K8
Canada
E-Mail Brian.Feagan@RobartsInc.com

Dr. Stacy A. Kahn
The University of Chicago Medicine
Section of Pediatric Gastroenterology, Hepatology & Nutrition
5841 S. Maryland Avenue, MC 4065
Chicago, IL 60637
USA
E-Mail skahn@peds.bsd.uchicago.edu

Prof. Arie Levine
Tel Aviv University
Pediatric Gastroenterology Unit
Wolfson Medical Center
62 Halohamim Street
Holon 58100
Israel
E-Mail arie.levine.dr@gmail.com

Prof. James D. Lewis
Division of Gastroenterology
Center for Clinical Epidemiology and Biostatistics
Perelman School of Medicine at the University of Pennsylvania
423 Guardian Drive, 720 Blockley Hall
Philadelphia, PA 19104-6021
USA
E-Mail lewisjd@mail.med.upenn.edu
Contributeurs

Dr. J. Rodrigo Mora
Disease Integrative Biology, Immunology TA
Janssen Research & Development, LLC
1400 McKean Road, 42-3114A
Spring House, PA 19477
USA
E-Mail jmora1@ITS.JNJ.com

Prof. Frank M. Ruemmele
Hospital Necker-Enfants Malades
149 Rue de Sèvres
FR–75015 Paris
France
E-Mail frank.ruemmele@nck.aphp.fr

Dr. Balfour Sartor
UNC School of Medicine
Midgette Distinguished Professor of Medicine, Microbiology and Immunology
7309A Medical Biomedical Research Building
Campus Box 7032
Chapel Hill, NC 27599-7032
USA
E-Mail rbs@med.unc.edu

Prof. Francisco A. Sylvester
Connecticut Children’s Medical Center
Department of Pediatrics
282 Washington Street
Hartford, CT 06105
USA
E-Mail fsylvester@uchc.edu

Prof. Gary Wu
University of Pennsylvania
Perelman School of Medicine
Ferdinand G. Weissbrod Chair in Gastroenterology
915 BRB II/III
421 Curie Blvd
Philadelphia, PA 19104
USA
E-Mail gdwu@mail.med.upenn.edu

Participants

Helene Lengline/France
Philippe Marteau/France
Berthold Koletzko/Germany
Sibylle Koletzko/Germany
Tarkan Karakan/Turkey
Meltem Sukan/Turkey
Bastiaan Oldenburg/The Netherlands
Wee Chian Lim/Singapore
Khoon Lin Ling/Singapore
Christina Ong/Singapore
Stephen Kin Kowk Tsao/Singapore
Jalil Benyacoub/Switzerland
Viral Brahmbhatt/Switzerland
Fernando Brito/Switzerland
Emil Chuang/Switzerland
Ferdinand Haschke/Switzerland
Martinas Kuslys/Switzerland
Grainne Mallon/Switzerland
Maryam Olesen/Switzerland
Pierre-Philippe Sagnier/Switzerland
Bruno Sobral/Switzerland
Natalia Wagemans/Switzerland
Jean Zetlaoui/Switzerland
Andrew Hart/UK
Maria Abreu/USA
Robert Baldassano/USA
Jonathan Braun/USA
Sean Colgan/USA
Nikky Contractor/USA
Jennifer Crawford/USA
Jason Hou/USA
Jess Kaplan/USA
Josh Korzenik/USA
Subra Kugathasan/USA
Dale Lee/USA
Barrett Levesque/USA
Juan Ochoa/USA
Jose Saavedra/USA
Lani San Mateo/USA
Bruce Sands/USA
Sam Shihabi/USA
Sharat Singh/USA
Laura Wingate/USA